



Oncology Agents- Autologous Cellular Immunotherapy (Car-T) (Yescarta)

WA.PHAR.83 Oncology Agents- Autologous Cellular Immunotherapy (Car-T) (Yescarta)

Effective Date: January 1, 2018

Background:

Axicabtagene ciloleucel (Yescarta™) is a CD19-directed, genetically modified, autologous T cell immunotherapy managed and paid by the Health Care Authority for Medicaid members.

All requests for authorization or payment must be referred to the Health Care Authority.

Coding:

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Code	Description
Q2041	KTE-C19 TO 200 M A ANTI-CD19 CAR POS T CE P TD

History

Date	Action and Summary of Changes
06/24/2020	<ul style="list-style-type: none">New Policy Created